OmniAb (OABI) Gains from Investment Securities (2022 - 2026)
OmniAb (OABI) reported Gains from Investment Securities of -$320000.0 for Q1 2026, down 24.03% year-over-year from -$421224.5 in Q1 2025, and down 28.51% quarter-over-quarter from -$249000.0 in Q4 2025.
OmniAb (OABI) Gains from Investment Securities (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Gains from Investment Securities data on file, last reported at -$320000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$320000.0, down 24.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$823000.0 (up 23.87% YoY), and the FY2025 annual result was -$761000.0, down 2051.28% from the prior year.
- Gains from Investment Securities fell to -$320000.0 in Q1 2026 per OABI's latest filing, from -$249000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.9 million in Q3 2024 and troughed at -$3.4 million in Q2 2024.
- A 5-year average of -$78352.9 and a median of -$93000.0 in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 431.06% in 2024 and fell as far as 8537.5% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $1.6 million in 2022, then tumbled by 114.95% to -$234000.0 in 2023, then jumped by 357.69% to $603000.0 in 2024, then slumped by 141.29% to -$249000.0 in 2025, then retreated by 28.51% to -$320000.0 in 2026.
- Business Quant data shows OABI's Gains from Investment Securities at -$320000.0 in Q1 2026, -$249000.0 in Q4 2025, and -$392000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -320,000.00 |
| Mar 31, 2026 | -320,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Sep 30, 2025 | -392,000.00 |
| Sep 30, 2025 | -392,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Mar 31, 2024 | 862,000.00 |
| Mar 31, 2024 | 862,000.00 |
| Dec 31, 2023 | -234,000.00 |
| Dec 31, 2023 | -234,000.00 |